Introgen Anticipates Completion Of Advexin Rolling BLA Submission In 2007
This article was originally published in The Pink Sheet Daily
Executive Summary
Biologic may have synergistic effects with ImClone’s Erbitux and Genentech’s Avastin, firm tells “The Pink Sheet” DAILY.
You may also be interested in...
Introgen Advexin Data Strengthens Biomarker Case In Head And Neck Cancer Patients
BLA filing for the p53 tumor suppressor remains on track for the second quarter, Medical and Scientific Affairs VP Sobol tells “The Pink Sheet” DAILY.
Introgen Advexin Data Strengthens Biomarker Case In Head And Neck Cancer Patients
BLA filing for the p53 tumor suppressor remains on track for the second quarter, Medical and Scientific Affairs VP Sobol tells “The Pink Sheet” DAILY.
Treanda Approved; Cephalon Ready With Tripled Salesforce To Launch In Chronic Lymphocytic Leukemia
Firm expects to ship product within 2-3 weeks, Cephalon tells “The Pink Sheet” DAILY.